QuidelOrtho 2025 Q2 Earnings Deeper Losses Amid Revenue Decline

QuidelOrtho (QDEL) reported earnings for fiscal 2025 Q2 on August 5, 2025, showing a decline in revenue and deeper losses than the prior year. The results fell short of expectations, with no guidance adjustments made for 2025.

Revenue
QuidelOrtho reported total revenue of $613.90 million in Q2 2025, a 3.6% decline compared to $637 million in Q2 2024. The Labs segment led with $369.70 million in revenue, followed by Transfusion Medicine, which generated $145.60 million. Immunohematology contributed $132.30 million, while the Point of Care segment brought in $93 million. Smaller segments, including Donor Screening and Molecular Diagnostics, reported revenues of $13.30 million and $5.60 million, respectively.

Earnings/Net Income
The company’s losses widened significantly, with a net loss of $255.40 million in Q2 2025, representing a 72.9% increase compared to the $147.70 million loss in Q2 2024. On a per-share basis, the loss expanded to $3.77, up from $2.20 per share in the prior year. These figures indicate a deterioration in profitability.

Price Action
Following the earnings release, the stock price of QuidelOrtho declined, falling 2.15% during the latest trading day, 6.92% over the past week, and 21.56% month-to-date.

Post Earnings Price Action Review
Over the past three years, the strategy of buying QuidelOrtho shares on the date of its earnings report and holding for 30 days has yielded a cumulative return of 17.3%, or an average annual return of 5.6%. This outperformed the NASDAQ Composite, which returned 6.5% over the same period, highlighting the strategy’s effectiveness in capturing gains following the company’s positive financial outlook. Strong performance was observed in specific quarters, such as a 10.8% rise in Q2 2024 and a 7.2% increase in Q4 2024. However, the strategy has also experienced volatility, with a 5.1% decline in Q1 2025 following an earnings report. Overall, the approach has demonstrated moderate success in aligning with QuidelOrtho’s financial trajectory, though volatility remains a key risk factor.

CEO Commentary
Brian J. Blaser, President and CEO, stated that the company delivered solid top and bottom-line results amid a challenging global environment. He highlighted $100 million in annualized cost savings, the acquisition of LEX Diagnostics, and the initiation of manufacturing site consolidation. Blaser expressed confidence in the company’s ability to create sustainable value for shareholders, customers, and employees based on year-to-date performance.

Guidance
QuidelOrtho reaffirmed its full-year 2025 guidance, including total revenue of $2.60–$2.81 billion, adjusted EBITDA of $575–$615 million, and adjusted diluted EPS of $2.07–$2.57. Foreign currency is expected to have a neutral impact for the full year.

Additional News
On July 29, 2025, QuidelOrtho announced the acquisition of LEX Diagnostics, a strategic move aimed at strengthening its diagnostic portfolio. The deal was accompanied by cost-saving initiatives, including the consolidation of manufacturing sites, which is expected to enhance operational efficiency. Mr. Joseph M. Busky, CPA, was confirmed as the company’s CFO, reinforcing leadership stability at the executive level. Institutional investors hold a minority stake, owning approximately 1.128 million shares of QDEL’s outstanding stock. Additionally, the company is currently being followed by three analysts, all of whom have issued a BUY rating for the stock. Analysts project an average price target of $47.14 over the next 12 months, implying significant upside potential for the stock.